LyGenesis’ work would help to make that possible. We envision a day when replacing organs will be as easy as replacing parts in a car. In particular, access to transplantable organs is an example of “new parts for people,” a strategy focused on technologies to make available replacement parts of our bodies, including organs, cartilage, bones and vasculature. It offers the kind of promise we imagined when we developed the seven strategies that guide Methuselah Foundation investments, planning and policies. In a bid to curb the illegal trade in human organs, the government has. The company is also exploring the use of lymph nodes to grow new thymuses, kidneys, and pancreases. Nearly two-thirds of Chinas transplanted organs come from executed prisoners, the Chinese state media reported last week. The company intends to use lymph nodes are organ generators. It will be guided by ultrasound to a target lymph node, which a surgeon will inject with healthy donor liver cells. LyGenesis delivers healthy liver cells using an endoscope that is fed down the throat. First, it maximizes use of available liver cells – potentially solving the liver shortage that costs so many lives. If this approach works in humans, it may be a game changer for people waiting for a liver transplant. About 10% of people waiting for a liver transplant in the U.S. Liver transplants are often recommended for people with this disease, but there are not enough donated livers to go around. People with the disease are at risk of diabetes, infections and liver cancer. The disease kills liver cells, and healthy tissue is replaced with scar tissue. LyGenesis will test its treatment in 12 adults with end-stage liver disease, a chronic liver failure that worsens over time. Why? Surgeons will not perform transplants on patients who are too week or too ill. The approach also overcomes some of the barriers to liver transplant because it is far less invasive than traditional procedures. It can use a relative handful of healthy cells from organs that would otherwise have been discarded and researchers tell MIT Technology Review they expect to get treatments for about 75 people from a single donated organ. The new approach promises to overcome both obstacles. Similarly, some people in need of transplants often cannot get them because they simply may not healthy enough to benefit from them. Donor organs are in short supply, and many cannot be used because they are too damaged. If the science works, the treatment could be revolutionary. LyGenesis hopes to save people who have serious liver diseases but are not eligible for transplants. Soon, we’ll find out if it works in people. The company has tested this approach in mice, pigs and dogs. The goal is to grow new miniature organs that will help compensate for an existing diseased one. LyGenesis, a Pittsburgh-based biotechnology company working to use a patient’s lymph nodes to grow functioning organs, will inject liver cells from a donor into the lymph nodes of sick recipients.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |